HALOZYME THERAPEUTICS, INC. Debt Conversion, Converted Instrument, Amount
HALOZYME THERAPEUTICS, INC. (HALO) reported Debt Conversion, Converted Instrument, Amount of $13.50 million for the 1-month period ending 2023-03-31, per its 10-Q filed 2024-10-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2024-10-31
- HALOZYME THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2021-03-31 was $7.87M.
- HALOZYME THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2020-03-31 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 1 month | Debt Conversion, Converted Instrument, Amount 1 month as first filed | Debt Conversion, Converted Instrument, Amount 3 month |
|---|---|---|---|
| 2023-03-31 | $13.50M 10-Q · filed 2024-10-31 | ||
| 2023-01-31 | $13.50M 10-K · filed 2024-02-20 | ||
| 2022-08-31 | $77.60M 10-K · filed 2024-02-20 | ||
| 2021-03-31 | $369.10M 10-Q · filed 2023-11-06 | $370.20M 10-Q · filed 2021-05-10 | $7.87M 10-Q · filed 2021-05-10 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |